drugset / Trial / NCT06571266
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
Timeline
- Start
- 2024-09-11
- Primary completion
- 2025-04-16
- Completion
- 2025-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.